Comprehensive, evidence-based information on research peptides and compounds. Our database covers peptides, research chemicals, and SARMs with detailed profiles on mechanisms of action, molecular structure, published research findings, and safety data.
Compounds that research suppliers stock in a pre-filled, dial-adjustable pen format — no reconstitution or measuring required. Select a compound to read its full research profile.
Filter compounds by research area, or select a category to explore its profiles.
Amyloid-beta 1-42, the aggregation-prone peptide fragment of amyloid precursor protein, studied extensively in Alzheimer's disease research.
Nucleoside analog and AMPK activator, studied for reproducing molecular effects of exercise on metabolism.
Third-generation non-steroidal aromatase inhibitor developed by AstraZeneca, studied for estrogen suppression in breast-cancer research.
Modified fragment of the C-terminus of human growth hormone, studied for effects on lipolysis and fat metabolism.
Synthetic hexapeptide developed by Lipotec; the prototypical topical neurocosmetic peptide, studied in expression-line research.
Water-soluble B-vitamin and essential coenzyme for carboxylase enzymes, studied in metabolic and dermatological research.
Body Protection Compound-157, a synthetic peptide derived from a gastric protein, studied for gastric and connective-tissue repair.
A research blend pairing BPC-157 and TB-500, two peptides studied together for tissue-repair and recovery applications.
Long-acting dopamine D2 receptor agonist, studied for suppression of prolactin in endocrine research.
Growth hormone-releasing hormone analog incorporating a Drug Affinity Complex, studied for extended growth hormone elevation.
Selective estrogen receptor modulator, studied for stimulation of gonadotropin release in ovulation and fertility research.
Short-acting selective serotonin reuptake inhibitor developed for on-demand use, studied in research on ejaculatory control.
Delta sleep-inducing peptide, an endogenous neuropeptide studied for its influence on sleep regulation and the stress response.
Dual 5-alpha-reductase inhibitor developed by GlaxoSmithKline, studied for suppression of dihydrotestosterone in hair-loss and prostate research.
Trans-isomer of clomiphene and a selective estrogen receptor modulator, studied for stimulating endogenous testosterone production.
Synthetic tetrapeptide modeled on a pineal gland peptide, developed in Russia and studied in telomerase and aging research.
Steroidal aromatase inhibitor that irreversibly inactivates the aromatase enzyme, studied in estrogen-suppression and breast-cancer research.
Recombinant form of the follistatin glycoprotein, studied as a myostatin-binding regulator in muscle-growth research.
Copper-binding tripeptide complex naturally present in human plasma, studied for skin remodeling and wound-healing research.
Synthetic growth hormone-releasing peptide and ghrelin receptor agonist, studied for stimulation of growth hormone secretion.
First-generation growth hormone-releasing peptide and ghrelin receptor agonist, studied for growth hormone release and appetite signaling.
A research peptide blend of GHK-Cu, BPC-157 and TB-500, studied together for skin, recovery and connective-tissue research.
Endogenous tripeptide of glutamate, cysteine and glycine, studied as the body's primary intracellular antioxidant and detoxification substrate.
PPAR-delta agonist developed by GlaxoSmithKline and Ligand Pharmaceuticals, studied for effects on endurance and fatty-acid metabolism.
Synthetic growth hormone secretagogue and ghrelin receptor agonist, studied for growth hormone release and cardiovascular research.
Truncated analog of insulin-like growth factor 1 missing three N-terminal residues, studied for localized growth-factor signaling.
Long-acting analog of insulin-like growth factor 1 with an extended half-life, studied for anabolic and growth-factor signaling research.
Selective growth hormone secretagogue and ghrelin receptor agonist, studied for growth hormone release with minimal effect on other hormones.
Second-generation antihistamine and mast-cell stabilizer, studied in allergic-response and mast-cell research.
Active fragment of the kisspeptin neuropeptide, studied for its role in initiating gonadotropin-releasing hormone secretion.
A multi-peptide research blend of GHK-Cu, BPC-157, TB-500 and KPV, studied for combined skin, recovery and anti-inflammatory research.
Tripeptide fragment of alpha-melanocyte-stimulating hormone, studied for anti-inflammatory activity in gut and skin research.
Amino acid derivative central to the transport of fatty acids into mitochondria, studied in energy-metabolism and exercise research.
Third-generation non-steroidal aromatase inhibitor developed by Novartis, studied in estrogen-suppression and breast-cancer research.
Non-steroidal selective androgen receptor modulator developed by Ligand Pharmaceuticals, studied for anabolic activity in muscle and bone research.
Synthetic form of the active thyroid hormone triiodothyronine, studied in thyroid-replacement and metabolic research.
Palmitoylated pentapeptide (Palmitoyl Pentapeptide-4), studied as a matrix-stimulating peptide in topical skin research.
Synthetic cyclic analog of alpha-melanocyte-stimulating hormone, studied for melanogenesis and sexual-function research.
Non-steroidal selective androgen receptor modulator developed by GTx, studied for muscle preservation in wasting-condition research.
Orally active non-peptide growth hormone secretagogue and ghrelin receptor agonist, studied for sustained growth hormone and IGF-1 elevation.
Modified growth hormone-releasing hormone analog, studied for stimulation of endogenous growth hormone secretion.
Mitochondrial-derived peptide encoded within mitochondrial DNA, studied for its role in metabolic regulation and exercise physiology.
Nicotinamide adenine dinucleotide, a coenzyme central to cellular redox metabolism, studied in sirtuin-signaling and DNA-repair research.
A fixed-ratio research blend of the energy coenzyme NAD+ and essential vitamin B12. Each component is well studied individually; the combination has not been formally trialed.
A research blend combining NAD+, its precursor NMN, and vitamin B12. The individual compounds are studied; the three-part combination has not been evaluated in trials.
Endogenous neuropeptide hormone produced in the hypothalamus, studied for roles in social bonding, lactation and reproductive physiology.
Non-ergot dopamine D2/D3 receptor agonist, studied in Parkinson's disease and restless-legs syndrome research.
Cyclic melanocortin receptor agonist derived from melanotan II, studied for effects on sexual arousal in neuroendocrine research.
Non-steroidal selective androgen receptor modulator developed by Radius Health, studied for anabolic activity with reduced androgenic effect.
Second-generation selective estrogen receptor modulator developed by Eli Lilly, studied in bone-density and estrogen-signaling research.
Triple GIP, GLP-1 and glucagon receptor agonist developed by Eli Lilly, studied in metabolic and weight-regulation research.
Non-steroidal selective androgen receptor modulator developed by GTx, studied for anabolic activity in muscle and bone research.
Synthetic analog of the immunomodulatory peptide tuftsin, developed in Russia and studied for anxiolytic and immune-regulating activity.
Long-acting glucagon-like peptide-1 receptor agonist developed by Novo Nordisk, studied extensively in metabolic and weight-regulation research.
Synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone, developed in Russia and studied for nootropic and neuroprotective activity.
Synthetic analog of growth hormone-releasing hormone, studied for stimulation of endogenous growth hormone secretion.
Phosphodiesterase type-5 inhibitor developed by Pfizer, studied for vasodilation in erectile-function and pulmonary-hypertension research.
Rev-ErbA agonist developed at Scripps Research, studied for effects on circadian rhythm and metabolic activity.
Long-acting phosphodiesterase type-5 inhibitor developed by ICOS and Eli Lilly, studied for vasodilation in erectile-function research.
Selective estrogen receptor modulator and a longstanding reference compound in breast-cancer and hormonal research.
Synthetic version of the active region of thymosin beta-4, studied for actin regulation in tissue-repair research.
Stabilized growth hormone-releasing hormone analog developed by Theratechnologies, studied for reduction of visceral adipose tissue.
Immunomodulatory peptide derived from thymosin fraction 5, studied for regulation of T-cell function in immune research.
Dual GIP and GLP-1 receptor agonist developed by Eli Lilly, studied extensively in metabolic and glucose-regulation research.
Selective estrogen receptor modulator developed by Orion Pharma, studied in breast-cancer and hormonal research.
Synthetic gonadotropin-releasing hormone agonist, studied for its effects on the hypothalamic-pituitary-gonadal axis.
Steroidal selective androgen receptor modulator that also acts as a myostatin inhibitor, studied in muscle research.
How RAD-140 and LGD-4033 compare on mechanism, trial findings, suppression and liver signals, and the regulatory and quality issues that surround SARMs.
What enclomiphene is, how it raises testosterone through the HPG axis, why it differs from TRT on fertility, and its clinical evidence and regulatory status.
What NAD+ is, why its age-related decline matters, how it differs from precursors like NMN and NR, and what human trials have and have not demonstrated.
Common questions about research peptides and how peptides.fyi compiles its compound profiles.
Research peptides are short chains of amino acids used in scientific and clinical studies to understand biological mechanisms. They are not approved for human therapeutic use outside of specific FDA-approved compounds like semaglutide and tirzepatide.
Each peptide profile on peptides.fyi is compiled from published peer-reviewed research, clinical trial data, and established pharmacological references. We cite specific studies where possible and update profiles as new data becomes available.
No. peptides.fyi is an independent educational resource. We do not sell any products. Some pages contain affiliate links to third-party suppliers, which are clearly disclosed.
FDA-approved peptides like semaglutide and tirzepatide have completed Phase 3 clinical trials and received regulatory approval for specific medical conditions. Research peptides are compounds still under investigation in preclinical or early clinical studies and are not approved for therapeutic use.
Join our newsletter for weekly peptide research updates, new study summaries, and exclusive content delivered to your inbox.
